Purpose - NPAIHB



Guidelines for Screening, Management and pre-treatment work-up for Hepatitis C virus (hCv) Within IHS, Tribal and urban Indian Healthcare FacilitiesThis template is a sample policy for HCV screening, follow up, and treatment. This is a template, and as such it is not comprehensive and does not mandate any clinical activities. It does provide a sample policy for I/T/U facilities to provide a range of HCV services at the primary care level, and should be adapted as needed to reflect local conditions and priorities. An HCV policy can be instrumental for clinical staff to understand HCV patient needs, clinical algorithms, and best practices. American Indians/Alaska Natives have the highest rate of mortality from HCV all I/T/U facilities are encouraged to provide early detection and linkage to care. For further questions or support, contact Dr. Jonathan Iralu, Chief Clinical Consultant, Infectious Disease, jonathan.iralu@PurposeTo expand screening, management and pre-treatment care for HCV infection. backgroundIn the United States, an estimated 3 million persons are chronically infected with HCV. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EZW5uaXN0b248L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFy

PjxSZWNOdW0+MjwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMV08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+MjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9InAyMHo5cHY5OWZwZjI2ZWZmcmtwcHdkMTl0enZzeGE5dGR2eCIgdGltZXN0YW1wPSIxNDE0

NDQ4MTIzIj4yPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0

aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5EZW5uaXN0

b24sIE0uIE0uPC9hdXRob3I+PGF1dGhvcj5KaWxlcywgUi4gQi48L2F1dGhvcj48YXV0aG9yPkRy

b2Jlbml1YywgSi48L2F1dGhvcj48YXV0aG9yPktsZXZlbnMsIFIuIE0uPC9hdXRob3I+PGF1dGhv

cj5XYXJkLCBKLiBXLjwvYXV0aG9yPjxhdXRob3I+TWNRdWlsbGFuLCBHLiBNLjwvYXV0aG9yPjxh

dXRob3I+SG9sbWJlcmcsIFMuIEQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0

aXRsZXM+PHRpdGxlPkNocm9uaWMgaGVwYXRpdGlzIEMgdmlydXMgaW5mZWN0aW9uIGluIHRoZSBV

bml0ZWQgU3RhdGVzLCBOYXRpb25hbCBIZWFsdGggYW5kIE51dHJpdGlvbiBFeGFtaW5hdGlvbiBT

dXJ2ZXkgMjAwMyB0byAyMDEwPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkFubiBJbnRlcm4gTWVk

PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5Bbm5hbHMgb2YgaW50ZXJuYWwgbWVkaWNpbmU8

L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Bbm4gSW50ZXJuIE1l

ZDwvZnVsbC10aXRsZT48YWJici0xPkFubmFscyBvZiBpbnRlcm5hbCBtZWRpY2luZTwvYWJici0x

PjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW5uIEludGVybiBNZWQ8

L2Z1bGwtdGl0bGU+PGFiYnItMT5Bbm5hbHMgb2YgaW50ZXJuYWwgbWVkaWNpbmU8L2FiYnItMT48

L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4yOTMtMzAwPC9wYWdlcz48dm9sdW1lPjE2MDwvdm9sdW1l

PjxudW1iZXI+NTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5

d29yZD5CbG9vZCBUcmFuc2Z1c2lvbi9hZHZlcnNlIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+

RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkhlcGFjaXZpcnVzL2lzb2xhdGlvbiAmYW1wOyBwdXJp

ZmljYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+SGVwYXRpdGlzIEMgQW50aWJvZGllcy9ibG9vZDwv

a2V5d29yZD48a2V5d29yZD5IZXBhdGl0aXMgQywgQ2hyb25pYy8qZXBpZGVtaW9sb2d5PC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk51dHJpdGlvbiBTdXJ2ZXlzPC9rZXl3

b3JkPjxrZXl3b3JkPlByZXZhbGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+Uk5BLCBWaXJhbC9hbmFs

eXNpczwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U3Vi

c3RhbmNlLVJlbGF0ZWQgRGlzb3JkZXJzL2NvbXBsaWNhdGlvbnM8L2tleXdvcmQ+PGtleXdvcmQ+

VW5pdGVkIFN0YXRlcy9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+WW91bmcgQWR1bHQ8

L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNDwveWVhcj48cHViLWRhdGVzPjxk

YXRlPk1hciA0PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTUzOS0zNzA0IChFbGVj

dHJvbmljKSYjeEQ7MDAwMy00ODE5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNDcz

NzI3MTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5u

Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNDczNzI3MTwvdXJsPjx1cmw+aHR0cDovL2FubmFscy5v

cmcvZGF0YS9Kb3VybmFscy9BSU0vOTI5ODExLzAwMDA2MDUtMjAxNDAzMDQwLTAwMDAzLnBkZjwv

dXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuNzMy

Ni9NMTMtMTEzMzwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT4A

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5EZW5uaXN0b248L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFy

PjxSZWNOdW0+MjwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMV08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+MjwvcmVjLW51bWJlcj48Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGIt

aWQ9InAyMHo5cHY5OWZwZjI2ZWZmcmtwcHdkMTl0enZzeGE5dGR2eCIgdGltZXN0YW1wPSIxNDE0

NDQ4MTIzIj4yPC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwgQXJ0

aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5EZW5uaXN0

b24sIE0uIE0uPC9hdXRob3I+PGF1dGhvcj5KaWxlcywgUi4gQi48L2F1dGhvcj48YXV0aG9yPkRy

b2Jlbml1YywgSi48L2F1dGhvcj48YXV0aG9yPktsZXZlbnMsIFIuIE0uPC9hdXRob3I+PGF1dGhv

cj5XYXJkLCBKLiBXLjwvYXV0aG9yPjxhdXRob3I+TWNRdWlsbGFuLCBHLiBNLjwvYXV0aG9yPjxh

dXRob3I+SG9sbWJlcmcsIFMuIEQuPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjx0

aXRsZXM+PHRpdGxlPkNocm9uaWMgaGVwYXRpdGlzIEMgdmlydXMgaW5mZWN0aW9uIGluIHRoZSBV

bml0ZWQgU3RhdGVzLCBOYXRpb25hbCBIZWFsdGggYW5kIE51dHJpdGlvbiBFeGFtaW5hdGlvbiBT

dXJ2ZXkgMjAwMyB0byAyMDEwPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkFubiBJbnRlcm4gTWVk

PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5Bbm5hbHMgb2YgaW50ZXJuYWwgbWVkaWNpbmU8

L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRsZT5Bbm4gSW50ZXJuIE1l

ZDwvZnVsbC10aXRsZT48YWJici0xPkFubmFscyBvZiBpbnRlcm5hbCBtZWRpY2luZTwvYWJici0x

PjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+QW5uIEludGVybiBNZWQ8

L2Z1bGwtdGl0bGU+PGFiYnItMT5Bbm5hbHMgb2YgaW50ZXJuYWwgbWVkaWNpbmU8L2FiYnItMT48

L2FsdC1wZXJpb2RpY2FsPjxwYWdlcz4yOTMtMzAwPC9wYWdlcz48dm9sdW1lPjE2MDwvdm9sdW1l

PjxudW1iZXI+NTwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5

d29yZD5CbG9vZCBUcmFuc2Z1c2lvbi9hZHZlcnNlIGVmZmVjdHM8L2tleXdvcmQ+PGtleXdvcmQ+

RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkhlcGFjaXZpcnVzL2lzb2xhdGlvbiAmYW1wOyBwdXJp

ZmljYXRpb248L2tleXdvcmQ+PGtleXdvcmQ+SGVwYXRpdGlzIEMgQW50aWJvZGllcy9ibG9vZDwv

a2V5d29yZD48a2V5d29yZD5IZXBhdGl0aXMgQywgQ2hyb25pYy8qZXBpZGVtaW9sb2d5PC9rZXl3

b3JkPjxrZXl3b3JkPkh1bWFuczwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3

b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk51dHJpdGlvbiBTdXJ2ZXlzPC9rZXl3

b3JkPjxrZXl3b3JkPlByZXZhbGVuY2U8L2tleXdvcmQ+PGtleXdvcmQ+Uk5BLCBWaXJhbC9hbmFs

eXNpczwva2V5d29yZD48a2V5d29yZD5SaXNrIEZhY3RvcnM8L2tleXdvcmQ+PGtleXdvcmQ+U3Vi

c3RhbmNlLVJlbGF0ZWQgRGlzb3JkZXJzL2NvbXBsaWNhdGlvbnM8L2tleXdvcmQ+PGtleXdvcmQ+

VW5pdGVkIFN0YXRlcy9lcGlkZW1pb2xvZ3k8L2tleXdvcmQ+PGtleXdvcmQ+WW91bmcgQWR1bHQ8

L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+MjAxNDwveWVhcj48cHViLWRhdGVzPjxk

YXRlPk1hciA0PC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTUzOS0zNzA0IChFbGVj

dHJvbmljKSYjeEQ7MDAwMy00ODE5IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNDcz

NzI3MTwvYWNjZXNzaW9uLW51bT48dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5u

Y2JpLm5sbS5uaWguZ292L3B1Ym1lZC8yNDczNzI3MTwvdXJsPjx1cmw+aHR0cDovL2FubmFscy5v

cmcvZGF0YS9Kb3VybmFscy9BSU0vOTI5ODExLzAwMDA2MDUtMjAxNDAzMDQwLTAwMDAzLnBkZjwv

dXJsPjwvcmVsYXRlZC11cmxzPjwvdXJscz48ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuNzMy

Ni9NMTMtMTEzMzwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5k

Tm90ZT4A

ADDIN EN.CITE.DATA [1] Compared to other racial and ethnic groups, AI/ANs experience a higher rate of acute HCV incidence and one that has increased more quickly. ADDIN EN.CITE <EndNote><Cite><Author>Prevention</Author><Year>2014</Year><RecNum>3</RecNum><DisplayText>[2]</DisplayText><record><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="p20z9pv99fpf26effrkppwd19tzvsxa9tdvx" timestamp="1414450607">3</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Centers for Disease Control and Prevention</author></authors></contributors><titles><title>Surveillance for Viral Hepatitis – United States, 2012</title></titles><volume>2014</volume><number>10/27</number><dates><year>2014</year><pub-dates><date>9/2/14</date></pub-dates></dates><urls><related-urls><url>;[2] Compared to whites, AI/ANs experience a three-fold higher death rate from chronic liver disease—one of the multiple complications of chronic HCV infection. PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdXJ5YXByYXNhZDwvQXV0aG9yPjxZZWFyPjIwMTQ8L1ll

YXI+PFJlY051bT4xPC9SZWNOdW0+PERpc3BsYXlUZXh0PlszXTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4xPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0icDIwejlwdjk5ZnBmMjZlZmZya3Bwd2QxOXR6dnN4YTl0ZHZ4IiB0aW1lc3RhbXA9IjE0

MTQ0NDQwMzQiPjE8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlN1cnlh

cHJhc2FkLCBBLjwvYXV0aG9yPjxhdXRob3I+QnlyZCwgSy4gSy48L2F1dGhvcj48YXV0aG9yPlJl

ZGQsIEouIFQuPC9hdXRob3I+PGF1dGhvcj5QZXJkdWUsIEQuIEcuPC9hdXRob3I+PGF1dGhvcj5N

YW5vcywgTS4gTS48L2F1dGhvcj48YXV0aG9yPk1jTWFob24sIEIuIEouPC9hdXRob3I+PC9hdXRo

b3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+QW5pbCBTdXJ5YXByYXNhZCBhbmQgS2F0

aHkgSy4gQnlyZCBhcmUgd2l0aCB0aGUgRGl2aXNpb24gb2YgVmlyYWwgSGVwYXRpdGlzOyBOYXRp

b25hbCBDZW50ZXIgZm9yIEhJVi9BSURTLCBWaXJhbCBIZXBhdGl0aXMsIFNURCwgYW5kIFRCIFBy

ZXZlbnRpb247IENlbnRlcnMgZm9yIERpc2Vhc2UgQ29udHJvbCBhbmQgUHJldmVudGlvbiAoQ0RD

KTsgVVMgRGVwYXJ0bWVudCBvZiBIZWFsdGggYW5kIEh1bWFuIFNlcnZpY2VzOyBBdGxhbnRhLCBH

QS4gSm9obiBULiBSZWRkIGlzIHdpdGggdGhlIFNhbnRhIEZlIFB1YmxpYyBIZWFsdGggU2Vydmlj

ZSBJbmRpYW4gSG9zcGl0YWwsIEluZGlhbiBIZWFsdGggU2VydmljZSwgVVMgRGVwYXJ0bWVudCBv

ZiBIZWFsdGggYW5kIEh1bWFuIFNlcnZpY2VzLCBTYW50YSBGZSwgTk0uIERhdmlkIEcuIFBlcmR1

ZSBpcyB3aXRoIHRoZSBBbWVyaWNhbiBJbmRpYW4gQ2FuY2VyIEZvdW5kYXRpb24gYW5kIE1pbm5l

c290YSBHYXN0cm9lbnRlcm9sb2d5IFBBLCBNaW5uZWFwb2xpcy4gTS4gTWljaGVsZSBNYW5vcyBp

cyB3aXRoIHRoZSBLYWlzZXIgUGVybWFuZW50ZSBEaXZpc2lvbiBvZiBSZXNlYXJjaCwgT2FrbGFu

ZCwgQ0EuIEJyaWFuIEouIE1jTWFob24gaXMgd2l0aCB0aGUgQXJjdGljIEludmVzdGlnYXRpb25z

IFByb2dyYW0sIERpdmlzaW9uIG9mIFByZXBhcmVkbmVzcyBhbmQgRW1lcmdpbmcgSW5mZWN0aW9u

cywgTmF0aW9uYWwgQ2VudGVyIGZvciBFbWVyZ2luZyBhbmQgWm9vbm90aWMgSW5mZWN0aW91cyBE

aXNlYXNlcywgQ2VudGVycyBmb3IgRGlzZWFzZSBDb250cm9sIGFuZCBQcmV2ZW50aW9uLCBBbmNo

b3JhZ2UsIEFMLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPk1vcnRhbGl0eSBjYXVzZWQg

YnkgY2hyb25pYyBsaXZlciBkaXNlYXNlIGFtb25nIEFtZXJpY2FuIEluZGlhbnMgYW5kIEFsYXNr

YSBOYXRpdmVzIGluIHRoZSBVbml0ZWQgU3RhdGVzLCAxOTk5LTIwMDk8L3RpdGxlPjxzZWNvbmRh

cnktdGl0bGU+QW0gSiBQdWJsaWMgSGVhbHRoPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5B

bWVyaWNhbiBqb3VybmFsIG9mIHB1YmxpYyBoZWFsdGg8L2FsdC10aXRsZT48L3RpdGxlcz48cGVy

aW9kaWNhbD48ZnVsbC10aXRsZT5BbSBKIFB1YmxpYyBIZWFsdGg8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5BbWVyaWNhbiBqb3VybmFsIG9mIHB1YmxpYyBoZWFsdGg8L2FiYnItMT48L3BlcmlvZGljYWw+

PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkFtIEogUHVibGljIEhlYWx0aDwvZnVsbC10aXRs

ZT48YWJici0xPkFtZXJpY2FuIGpvdXJuYWwgb2YgcHVibGljIGhlYWx0aDwvYWJici0xPjwvYWx0

LXBlcmlvZGljYWw+PHBhZ2VzPlMzNTAtODwvcGFnZXM+PHZvbHVtZT4xMDQgU3VwcGwgMzwvdm9s

dW1lPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2UgRGlzdHJp

YnV0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdlZCwgODAg

YW5kIG92ZXI8L2tleXdvcmQ+PGtleXdvcmQ+QWxhc2thL2VwaWRlbWlvbG9neTwva2V5d29yZD48

a2V5d29yZD5DYXVzZSBvZiBEZWF0aDwva2V5d29yZD48a2V5d29yZD5DaHJvbmljIERpc2Vhc2U8

L2tleXdvcmQ+PGtleXdvcmQ+RGVhdGggQ2VydGlmaWNhdGVzPC9rZXl3b3JkPjxrZXl3b3JkPkV1

cm9wZWFuIENvbnRpbmVudGFsIEFuY2VzdHJ5IEdyb3VwL3N0YXRpc3RpY3MgJmFtcDsgbnVtZXJp

Y2FsIGRhdGE8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFu

czwva2V5d29yZD48a2V5d29yZD5JbmRpYW5zLCBOb3J0aCBBbWVyaWNhbi8qc3RhdGlzdGljcyAm

YW1wOyBudW1lcmljYWwgZGF0YTwva2V5d29yZD48a2V5d29yZD5JbnVpdHMvKnN0YXRpc3RpY3Mg

JmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdvcmQ+PGtleXdvcmQ+TGl2ZXIgRGlzZWFzZXMvKmV0

aG5vbG9neS8qbW9ydGFsaXR5PC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+PGtleXdv

cmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+U2V4IERpc3RyaWJ1dGlvbjwva2V5d29y

ZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzL2VwaWRlbWlvbG9neTwva2V5d29yZD48L2tleXdvcmRz

PjxkYXRlcz48eWVhcj4yMDE0PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVuPC9kYXRlPjwvcHVi

LWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTU0MS0wMDQ4IChFbGVjdHJvbmljKSYjeEQ7MDA5MC0wMDM2

IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNDc1NDYxNjwvYWNjZXNzaW9uLW51bT48

dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1l

ZC8yNDc1NDYxNjwvdXJsPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRp

Y2xlcy9QTUM0MDM1ODY4L3BkZi9BSlBILjIwMTMuMzAxNjQ1LnBkZjwvdXJsPjwvcmVsYXRlZC11

cmxzPjwvdXJscz48Y3VzdG9tMj40MDM1ODY4PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNl

LW51bT4xMC4yMTA1L0FKUEguMjAxMy4zMDE2NDU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv

cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TdXJ5YXByYXNhZDwvQXV0aG9yPjxZZWFyPjIwMTQ8L1ll

YXI+PFJlY051bT4xPC9SZWNOdW0+PERpc3BsYXlUZXh0PlszXTwvRGlzcGxheVRleHQ+PHJlY29y

ZD48cmVjLW51bWJlcj4xPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0icDIwejlwdjk5ZnBmMjZlZmZya3Bwd2QxOXR6dnN4YTl0ZHZ4IiB0aW1lc3RhbXA9IjE0

MTQ0NDQwMzQiPjE8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlN1cnlh

cHJhc2FkLCBBLjwvYXV0aG9yPjxhdXRob3I+QnlyZCwgSy4gSy48L2F1dGhvcj48YXV0aG9yPlJl

ZGQsIEouIFQuPC9hdXRob3I+PGF1dGhvcj5QZXJkdWUsIEQuIEcuPC9hdXRob3I+PGF1dGhvcj5N

YW5vcywgTS4gTS48L2F1dGhvcj48YXV0aG9yPk1jTWFob24sIEIuIEouPC9hdXRob3I+PC9hdXRo

b3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFkZHJlc3M+QW5pbCBTdXJ5YXByYXNhZCBhbmQgS2F0

aHkgSy4gQnlyZCBhcmUgd2l0aCB0aGUgRGl2aXNpb24gb2YgVmlyYWwgSGVwYXRpdGlzOyBOYXRp

b25hbCBDZW50ZXIgZm9yIEhJVi9BSURTLCBWaXJhbCBIZXBhdGl0aXMsIFNURCwgYW5kIFRCIFBy

ZXZlbnRpb247IENlbnRlcnMgZm9yIERpc2Vhc2UgQ29udHJvbCBhbmQgUHJldmVudGlvbiAoQ0RD

KTsgVVMgRGVwYXJ0bWVudCBvZiBIZWFsdGggYW5kIEh1bWFuIFNlcnZpY2VzOyBBdGxhbnRhLCBH

QS4gSm9obiBULiBSZWRkIGlzIHdpdGggdGhlIFNhbnRhIEZlIFB1YmxpYyBIZWFsdGggU2Vydmlj

ZSBJbmRpYW4gSG9zcGl0YWwsIEluZGlhbiBIZWFsdGggU2VydmljZSwgVVMgRGVwYXJ0bWVudCBv

ZiBIZWFsdGggYW5kIEh1bWFuIFNlcnZpY2VzLCBTYW50YSBGZSwgTk0uIERhdmlkIEcuIFBlcmR1

ZSBpcyB3aXRoIHRoZSBBbWVyaWNhbiBJbmRpYW4gQ2FuY2VyIEZvdW5kYXRpb24gYW5kIE1pbm5l

c290YSBHYXN0cm9lbnRlcm9sb2d5IFBBLCBNaW5uZWFwb2xpcy4gTS4gTWljaGVsZSBNYW5vcyBp

cyB3aXRoIHRoZSBLYWlzZXIgUGVybWFuZW50ZSBEaXZpc2lvbiBvZiBSZXNlYXJjaCwgT2FrbGFu

ZCwgQ0EuIEJyaWFuIEouIE1jTWFob24gaXMgd2l0aCB0aGUgQXJjdGljIEludmVzdGlnYXRpb25z

IFByb2dyYW0sIERpdmlzaW9uIG9mIFByZXBhcmVkbmVzcyBhbmQgRW1lcmdpbmcgSW5mZWN0aW9u

cywgTmF0aW9uYWwgQ2VudGVyIGZvciBFbWVyZ2luZyBhbmQgWm9vbm90aWMgSW5mZWN0aW91cyBE

aXNlYXNlcywgQ2VudGVycyBmb3IgRGlzZWFzZSBDb250cm9sIGFuZCBQcmV2ZW50aW9uLCBBbmNo

b3JhZ2UsIEFMLjwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxlPk1vcnRhbGl0eSBjYXVzZWQg

YnkgY2hyb25pYyBsaXZlciBkaXNlYXNlIGFtb25nIEFtZXJpY2FuIEluZGlhbnMgYW5kIEFsYXNr

YSBOYXRpdmVzIGluIHRoZSBVbml0ZWQgU3RhdGVzLCAxOTk5LTIwMDk8L3RpdGxlPjxzZWNvbmRh

cnktdGl0bGU+QW0gSiBQdWJsaWMgSGVhbHRoPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5B

bWVyaWNhbiBqb3VybmFsIG9mIHB1YmxpYyBoZWFsdGg8L2FsdC10aXRsZT48L3RpdGxlcz48cGVy

aW9kaWNhbD48ZnVsbC10aXRsZT5BbSBKIFB1YmxpYyBIZWFsdGg8L2Z1bGwtdGl0bGU+PGFiYnIt

MT5BbWVyaWNhbiBqb3VybmFsIG9mIHB1YmxpYyBoZWFsdGg8L2FiYnItMT48L3BlcmlvZGljYWw+

PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkFtIEogUHVibGljIEhlYWx0aDwvZnVsbC10aXRs

ZT48YWJici0xPkFtZXJpY2FuIGpvdXJuYWwgb2YgcHVibGljIGhlYWx0aDwvYWJici0xPjwvYWx0

LXBlcmlvZGljYWw+PHBhZ2VzPlMzNTAtODwvcGFnZXM+PHZvbHVtZT4xMDQgU3VwcGwgMzwvdm9s

dW1lPjxrZXl3b3Jkcz48a2V5d29yZD5BZHVsdDwva2V5d29yZD48a2V5d29yZD5BZ2UgRGlzdHJp

YnV0aW9uPC9rZXl3b3JkPjxrZXl3b3JkPkFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdlZCwgODAg

YW5kIG92ZXI8L2tleXdvcmQ+PGtleXdvcmQ+QWxhc2thL2VwaWRlbWlvbG9neTwva2V5d29yZD48

a2V5d29yZD5DYXVzZSBvZiBEZWF0aDwva2V5d29yZD48a2V5d29yZD5DaHJvbmljIERpc2Vhc2U8

L2tleXdvcmQ+PGtleXdvcmQ+RGVhdGggQ2VydGlmaWNhdGVzPC9rZXl3b3JkPjxrZXl3b3JkPkV1

cm9wZWFuIENvbnRpbmVudGFsIEFuY2VzdHJ5IEdyb3VwL3N0YXRpc3RpY3MgJmFtcDsgbnVtZXJp

Y2FsIGRhdGE8L2tleXdvcmQ+PGtleXdvcmQ+RmVtYWxlPC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFu

czwva2V5d29yZD48a2V5d29yZD5JbmRpYW5zLCBOb3J0aCBBbWVyaWNhbi8qc3RhdGlzdGljcyAm

YW1wOyBudW1lcmljYWwgZGF0YTwva2V5d29yZD48a2V5d29yZD5JbnVpdHMvKnN0YXRpc3RpY3Mg

JmFtcDsgbnVtZXJpY2FsIGRhdGE8L2tleXdvcmQ+PGtleXdvcmQ+TGl2ZXIgRGlzZWFzZXMvKmV0

aG5vbG9neS8qbW9ydGFsaXR5PC9rZXl3b3JkPjxrZXl3b3JkPk1hbGU8L2tleXdvcmQ+PGtleXdv

cmQ+TWlkZGxlIEFnZWQ8L2tleXdvcmQ+PGtleXdvcmQ+U2V4IERpc3RyaWJ1dGlvbjwva2V5d29y

ZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzL2VwaWRlbWlvbG9neTwva2V5d29yZD48L2tleXdvcmRz

PjxkYXRlcz48eWVhcj4yMDE0PC95ZWFyPjxwdWItZGF0ZXM+PGRhdGU+SnVuPC9kYXRlPjwvcHVi

LWRhdGVzPjwvZGF0ZXM+PGlzYm4+MTU0MS0wMDQ4IChFbGVjdHJvbmljKSYjeEQ7MDA5MC0wMDM2

IChMaW5raW5nKTwvaXNibj48YWNjZXNzaW9uLW51bT4yNDc1NDYxNjwvYWNjZXNzaW9uLW51bT48

dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3B1Ym1l

ZC8yNDc1NDYxNjwvdXJsPjx1cmw+aHR0cDovL3d3dy5uY2JpLm5sbS5uaWguZ292L3BtYy9hcnRp

Y2xlcy9QTUM0MDM1ODY4L3BkZi9BSlBILjIwMTMuMzAxNjQ1LnBkZjwvdXJsPjwvcmVsYXRlZC11

cmxzPjwvdXJscz48Y3VzdG9tMj40MDM1ODY4PC9jdXN0b20yPjxlbGVjdHJvbmljLXJlc291cmNl

LW51bT4xMC4yMTA1L0FKUEguMjAxMy4zMDE2NDU8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjwv

cmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA [3]Certain practices pertaining to the screening, treatment, and management of HCV can prolong the length and quality of life of chronically infected patients. The American Association for the Study of Liver Diseases, the U.S. Preventive Services Task Force, and the Centers for Disease Control and Prevention endorse the below practices, as will IHS henceforth.Among those with HCV in the U.S., 50% do not realize they are infected.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Zb3Vub3NzaTwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+

PFJlY051bT4xMzwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bNF08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+MTM8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSJwMjB6OXB2OTlmcGYyNmVmZnJrcHB3ZDE5dHp2c3hhOXRkdngiIHRpbWVzdGFtcD0iMTQx

NzAzMjY3NiI+MTM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPllvdW5v

c3NpLCBaLiBNLjwvYXV0aG9yPjxhdXRob3I+U3RlcGFub3ZhLCBNLjwvYXV0aG9yPjxhdXRob3I+

QWZlbmR5LCBNLjwvYXV0aG9yPjxhdXRob3I+TGFtLCBCLiBQLjwvYXV0aG9yPjxhdXRob3I+TWlz

aHJhLCBBLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkJl

dHR5IGFuZCBHdXkgQmVhdHR5IENlbnRlciBmb3IgSW50ZWdyYXRlZCBSZXNlYXJjaCwgSW5vdmEg

SGVhbHRoIFN5c3RlbSwgRmFsbHMgQ2h1cmNoLCBWQSwgVVNBLiB6b2JhaXIueW91bm9zc2lAaW5v

dmEub3JnPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+S25vd2xlZGdlIGFib3V0IGluZmVj

dGlvbiBpcyB0aGUgb25seSBwcmVkaWN0b3Igb2YgdHJlYXRtZW50IGluIHBhdGllbnRzIHdpdGgg

Y2hyb25pYyBoZXBhdGl0aXMgQzwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5KIFZpcmFsIEhlcGF0

PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5Kb3VybmFsIG9mIHZpcmFsIGhlcGF0aXRpczwv

YWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogVmlyYWwgSGVwYXQ8

L2Z1bGwtdGl0bGU+PGFiYnItMT5Kb3VybmFsIG9mIHZpcmFsIGhlcGF0aXRpczwvYWJici0xPjwv

cGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBWaXJhbCBIZXBhdDwvZnVs

bC10aXRsZT48YWJici0xPkpvdXJuYWwgb2YgdmlyYWwgaGVwYXRpdGlzPC9hYmJyLTE+PC9hbHQt

cGVyaW9kaWNhbD48cGFnZXM+NTUwLTU8L3BhZ2VzPjx2b2x1bWU+MjA8L3ZvbHVtZT48bnVtYmVy

Pjg8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdl

ZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+KkhlYWx0aCBLbm93

bGVkZ2UsIEF0dGl0dWRlcywgUHJhY3RpY2U8L2tleXdvcmQ+PGtleXdvcmQ+SGVwYXRpdGlzIEMs

IENocm9uaWMvKmRpYWdub3Npcy8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFu

czwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9r

ZXl3b3JkPjxrZXl3b3JkPlBhdGllbnQgQWNjZXB0YW5jZSBvZiBIZWFsdGggQ2FyZS8qc3RhdGlz

dGljcyAmYW1wOyBudW1lcmljYWwgZGF0YTwva2V5d29yZD48a2V5d29yZD5RdWVzdGlvbm5haXJl

czwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRh

dGVzPjx5ZWFyPjIwMTM8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWc8L2RhdGU+PC9wdWItZGF0

ZXM+PC9kYXRlcz48aXNibj4xMzY1LTI4OTMgKEVsZWN0cm9uaWMpJiN4RDsxMzUyLTA1MDQgKExp

bmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIzODA4OTkzPC9hY2Nlc3Npb24tbnVtPjx1cmxz

PjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzIz

ODA4OTkzPC91cmw+PHVybD5odHRwOi8vb25saW5lbGlicmFyeS53aWxleS5jb20vc3RvcmUvMTAu

MTExMS9qdmguMTIwODAvYXNzZXQvanZoMTIwODAucGRmP3Y9MSZhbXA7dD1pMno0b2Q5diZhbXA7

cz03MTBkOTUzYjVkMGUzYTUyZGQwZDM2ZWU5YTJlYWU1ZTQwN2IwMmY3PC91cmw+PC9yZWxhdGVk

LXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTExL2p2aC4xMjA4MDwv

ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Zb3Vub3NzaTwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+

PFJlY051bT4xMzwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bNF08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+

PHJlYy1udW1iZXI+MTM8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRi

LWlkPSJwMjB6OXB2OTlmcGYyNmVmZnJrcHB3ZDE5dHp2c3hhOXRkdngiIHRpbWVzdGFtcD0iMTQx

NzAzMjY3NiI+MTM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBB

cnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPllvdW5v

c3NpLCBaLiBNLjwvYXV0aG9yPjxhdXRob3I+U3RlcGFub3ZhLCBNLjwvYXV0aG9yPjxhdXRob3I+

QWZlbmR5LCBNLjwvYXV0aG9yPjxhdXRob3I+TGFtLCBCLiBQLjwvYXV0aG9yPjxhdXRob3I+TWlz

aHJhLCBBLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPkJl

dHR5IGFuZCBHdXkgQmVhdHR5IENlbnRlciBmb3IgSW50ZWdyYXRlZCBSZXNlYXJjaCwgSW5vdmEg

SGVhbHRoIFN5c3RlbSwgRmFsbHMgQ2h1cmNoLCBWQSwgVVNBLiB6b2JhaXIueW91bm9zc2lAaW5v

dmEub3JnPC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+S25vd2xlZGdlIGFib3V0IGluZmVj

dGlvbiBpcyB0aGUgb25seSBwcmVkaWN0b3Igb2YgdHJlYXRtZW50IGluIHBhdGllbnRzIHdpdGgg

Y2hyb25pYyBoZXBhdGl0aXMgQzwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5KIFZpcmFsIEhlcGF0

PC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5Kb3VybmFsIG9mIHZpcmFsIGhlcGF0aXRpczwv

YWx0LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkogVmlyYWwgSGVwYXQ8

L2Z1bGwtdGl0bGU+PGFiYnItMT5Kb3VybmFsIG9mIHZpcmFsIGhlcGF0aXRpczwvYWJici0xPjwv

cGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+SiBWaXJhbCBIZXBhdDwvZnVs

bC10aXRsZT48YWJici0xPkpvdXJuYWwgb2YgdmlyYWwgaGVwYXRpdGlzPC9hYmJyLTE+PC9hbHQt

cGVyaW9kaWNhbD48cGFnZXM+NTUwLTU8L3BhZ2VzPjx2b2x1bWU+MjA8L3ZvbHVtZT48bnVtYmVy

Pjg8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWR1bHQ8L2tleXdvcmQ+PGtleXdvcmQ+QWdl

ZDwva2V5d29yZD48a2V5d29yZD5GZW1hbGU8L2tleXdvcmQ+PGtleXdvcmQ+KkhlYWx0aCBLbm93

bGVkZ2UsIEF0dGl0dWRlcywgUHJhY3RpY2U8L2tleXdvcmQ+PGtleXdvcmQ+SGVwYXRpdGlzIEMs

IENocm9uaWMvKmRpYWdub3Npcy8qZHJ1ZyB0aGVyYXB5PC9rZXl3b3JkPjxrZXl3b3JkPkh1bWFu

czwva2V5d29yZD48a2V5d29yZD5NYWxlPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9r

ZXl3b3JkPjxrZXl3b3JkPlBhdGllbnQgQWNjZXB0YW5jZSBvZiBIZWFsdGggQ2FyZS8qc3RhdGlz

dGljcyAmYW1wOyBudW1lcmljYWwgZGF0YTwva2V5d29yZD48a2V5d29yZD5RdWVzdGlvbm5haXJl

czwva2V5d29yZD48a2V5d29yZD5Vbml0ZWQgU3RhdGVzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRh

dGVzPjx5ZWFyPjIwMTM8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWc8L2RhdGU+PC9wdWItZGF0

ZXM+PC9kYXRlcz48aXNibj4xMzY1LTI4OTMgKEVsZWN0cm9uaWMpJiN4RDsxMzUyLTA1MDQgKExp

bmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIzODA4OTkzPC9hY2Nlc3Npb24tbnVtPjx1cmxz

PjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzIz

ODA4OTkzPC91cmw+PHVybD5odHRwOi8vb25saW5lbGlicmFyeS53aWxleS5jb20vc3RvcmUvMTAu

MTExMS9qdmguMTIwODAvYXNzZXQvanZoMTIwODAucGRmP3Y9MSZhbXA7dD1pMno0b2Q5diZhbXA7

cz03MTBkOTUzYjVkMGUzYTUyZGQwZDM2ZWU5YTJlYWU1ZTQwN2IwMmY3PC91cmw+PC9yZWxhdGVk

LXVybHM+PC91cmxzPjxlbGVjdHJvbmljLXJlc291cmNlLW51bT4xMC4xMTExL2p2aC4xMjA4MDwv

ZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PC9yZWNvcmQ+PC9DaXRlPjwvRW5kTm90ZT5=

ADDIN EN.CITE.DATA [4] To identify HCV-infected patients, IHS clinicians should screen high-risk patients and all patients born from 1945 to 1965 for the presence of HCV antibodies. Patients born 1945-1965 accounts for the majority of HCV infections due to various causes including medical exposures or having injected drugs during in the 1950s-1980s.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TbWl0aDwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJl

Y051bT4xMjwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bNV08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJl

Yy1udW1iZXI+MTI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlk

PSJwMjB6OXB2OTlmcGYyNmVmZnJrcHB3ZDE5dHp2c3hhOXRkdngiIHRpbWVzdGFtcD0iMTQxNzAz

MjA4NSI+MTI8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlNtaXRoLCBC

LiBELjwvYXV0aG9yPjxhdXRob3I+TW9yZ2FuLCBSLiBMLjwvYXV0aG9yPjxhdXRob3I+QmVja2V0

dCwgRy4gQS48L2F1dGhvcj48YXV0aG9yPkZhbGNrLVl0dGVyLCBZLjwvYXV0aG9yPjxhdXRob3I+

SG9sdHptYW4sIEQuPC9hdXRob3I+PGF1dGhvcj5UZW8sIEMuIEcuPC9hdXRob3I+PGF1dGhvcj5K

ZXdldHQsIEEuPC9hdXRob3I+PGF1dGhvcj5CYWFjaywgQi48L2F1dGhvcj48YXV0aG9yPlJlaW4s

IEQuIEIuPC9hdXRob3I+PGF1dGhvcj5QYXRlbCwgTi48L2F1dGhvcj48YXV0aG9yPkFsdGVyLCBN

LjwvYXV0aG9yPjxhdXRob3I+WWFydGVsLCBBLjwvYXV0aG9yPjxhdXRob3I+V2FyZCwgSi4gVy48

L2F1dGhvcj48YXV0aG9yPkNlbnRlcnMgZm9yIERpc2Vhc2UsIENvbnRyb2w8L2F1dGhvcj48YXV0

aG9yPlByZXZlbnRpb24sPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFk

ZHJlc3M+RGl2aXNpb24gb2YgVmlyYWwgSGVwYXRpdGlzLCBOYXRpb25hbCBDZW50ZXIgZm9yIEhJ

Vi9BSURTLCBWaXJhbCBIZXBhdGl0aXMsIFNURCwgYW5kIFRCIFByZXZlbnRpb24sIFVTQS4gYnNt

aXRoNkBjZGMuZ292PC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+UmVjb21tZW5kYXRpb25z

IGZvciB0aGUgaWRlbnRpZmljYXRpb24gb2YgY2hyb25pYyBoZXBhdGl0aXMgQyB2aXJ1cyBpbmZl

Y3Rpb24gYW1vbmcgcGVyc29ucyBib3JuIGR1cmluZyAxOTQ1LTE5NjU8L3RpdGxlPjxzZWNvbmRh

cnktdGl0bGU+TU1XUiBSZWNvbW0gUmVwPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5NTVdS

LiBSZWNvbW1lbmRhdGlvbnMgYW5kIHJlcG9ydHMgOiBNb3JiaWRpdHkgYW5kIG1vcnRhbGl0eSB3

ZWVrbHkgcmVwb3J0LiBSZWNvbW1lbmRhdGlvbnMgYW5kIHJlcG9ydHMgLyBDZW50ZXJzIGZvciBE

aXNlYXNlIENvbnRyb2w8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs

ZT5NTVdSIFJlY29tbSBSZXA8L2Z1bGwtdGl0bGU+PGFiYnItMT5NTVdSLiBSZWNvbW1lbmRhdGlv

bnMgYW5kIHJlcG9ydHMgOiBNb3JiaWRpdHkgYW5kIG1vcnRhbGl0eSB3ZWVrbHkgcmVwb3J0LiBS

ZWNvbW1lbmRhdGlvbnMgYW5kIHJlcG9ydHMgLyBDZW50ZXJzIGZvciBEaXNlYXNlIENvbnRyb2w8

L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk1NV1IgUmVj

b21tIFJlcDwvZnVsbC10aXRsZT48YWJici0xPk1NV1IuIFJlY29tbWVuZGF0aW9ucyBhbmQgcmVw

b3J0cyA6IE1vcmJpZGl0eSBhbmQgbW9ydGFsaXR5IHdlZWtseSByZXBvcnQuIFJlY29tbWVuZGF0

aW9ucyBhbmQgcmVwb3J0cyAvIENlbnRlcnMgZm9yIERpc2Vhc2UgQ29udHJvbDwvYWJici0xPjwv

YWx0LXBlcmlvZGljYWw+PHBhZ2VzPjEtMzI8L3BhZ2VzPjx2b2x1bWU+NjE8L3ZvbHVtZT48bnVt

YmVyPlJSLTQ8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29y

ZD5Db3Vuc2VsaW5nPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5I

ZXBhY2l2aXJ1cy8qaXNvbGF0aW9uICZhbXA7IHB1cmlmaWNhdGlvbjwva2V5d29yZD48a2V5d29y

ZD5IZXBhdGl0aXMgQywgQ2hyb25pYy9jb21wbGljYXRpb25zLypkaWFnbm9zaXMvbW9ydGFsaXR5

L3ByZXZlbnRpb24gJmFtcDsgY29udHJvbDwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdv

cmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NYXNzIFNjcmVlbmluZy8qc3RhbmRh

cmRzPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk91dGNv

bWUgQXNzZXNzbWVudCAoSGVhbHRoIENhcmUpPC9rZXl3b3JkPjxrZXl3b3JkPlByZXZhbGVuY2U8

L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlVuaXRlZCBT

dGF0ZXMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTI8

L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWcgMTc8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48

aXNibj4xNTQ1LTg2MDEgKEVsZWN0cm9uaWMpJiN4RDsxMDU3LTU5ODcgKExpbmtpbmcpPC9pc2Ju

PjxhY2Nlc3Npb24tbnVtPjIyODk1NDI5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVy

bHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzIyODk1NDI5PC91cmw+

PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TbWl0aDwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+PFJl

Y051bT4xMjwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bNV08L0Rpc3BsYXlUZXh0PjxyZWNvcmQ+PHJl

Yy1udW1iZXI+MTI8L3JlYy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlk

PSJwMjB6OXB2OTlmcGYyNmVmZnJrcHB3ZDE5dHp2c3hhOXRkdngiIHRpbWVzdGFtcD0iMTQxNzAz

MjA4NSI+MTI8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp

Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlNtaXRoLCBC

LiBELjwvYXV0aG9yPjxhdXRob3I+TW9yZ2FuLCBSLiBMLjwvYXV0aG9yPjxhdXRob3I+QmVja2V0

dCwgRy4gQS48L2F1dGhvcj48YXV0aG9yPkZhbGNrLVl0dGVyLCBZLjwvYXV0aG9yPjxhdXRob3I+

SG9sdHptYW4sIEQuPC9hdXRob3I+PGF1dGhvcj5UZW8sIEMuIEcuPC9hdXRob3I+PGF1dGhvcj5K

ZXdldHQsIEEuPC9hdXRob3I+PGF1dGhvcj5CYWFjaywgQi48L2F1dGhvcj48YXV0aG9yPlJlaW4s

IEQuIEIuPC9hdXRob3I+PGF1dGhvcj5QYXRlbCwgTi48L2F1dGhvcj48YXV0aG9yPkFsdGVyLCBN

LjwvYXV0aG9yPjxhdXRob3I+WWFydGVsLCBBLjwvYXV0aG9yPjxhdXRob3I+V2FyZCwgSi4gVy48

L2F1dGhvcj48YXV0aG9yPkNlbnRlcnMgZm9yIERpc2Vhc2UsIENvbnRyb2w8L2F1dGhvcj48YXV0

aG9yPlByZXZlbnRpb24sPC9hdXRob3I+PC9hdXRob3JzPjwvY29udHJpYnV0b3JzPjxhdXRoLWFk

ZHJlc3M+RGl2aXNpb24gb2YgVmlyYWwgSGVwYXRpdGlzLCBOYXRpb25hbCBDZW50ZXIgZm9yIEhJ

Vi9BSURTLCBWaXJhbCBIZXBhdGl0aXMsIFNURCwgYW5kIFRCIFByZXZlbnRpb24sIFVTQS4gYnNt

aXRoNkBjZGMuZ292PC9hdXRoLWFkZHJlc3M+PHRpdGxlcz48dGl0bGU+UmVjb21tZW5kYXRpb25z

IGZvciB0aGUgaWRlbnRpZmljYXRpb24gb2YgY2hyb25pYyBoZXBhdGl0aXMgQyB2aXJ1cyBpbmZl

Y3Rpb24gYW1vbmcgcGVyc29ucyBib3JuIGR1cmluZyAxOTQ1LTE5NjU8L3RpdGxlPjxzZWNvbmRh

cnktdGl0bGU+TU1XUiBSZWNvbW0gUmVwPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5NTVdS

LiBSZWNvbW1lbmRhdGlvbnMgYW5kIHJlcG9ydHMgOiBNb3JiaWRpdHkgYW5kIG1vcnRhbGl0eSB3

ZWVrbHkgcmVwb3J0LiBSZWNvbW1lbmRhdGlvbnMgYW5kIHJlcG9ydHMgLyBDZW50ZXJzIGZvciBE

aXNlYXNlIENvbnRyb2w8L2FsdC10aXRsZT48L3RpdGxlcz48cGVyaW9kaWNhbD48ZnVsbC10aXRs

ZT5NTVdSIFJlY29tbSBSZXA8L2Z1bGwtdGl0bGU+PGFiYnItMT5NTVdSLiBSZWNvbW1lbmRhdGlv

bnMgYW5kIHJlcG9ydHMgOiBNb3JiaWRpdHkgYW5kIG1vcnRhbGl0eSB3ZWVrbHkgcmVwb3J0LiBS

ZWNvbW1lbmRhdGlvbnMgYW5kIHJlcG9ydHMgLyBDZW50ZXJzIGZvciBEaXNlYXNlIENvbnRyb2w8

L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPk1NV1IgUmVj

b21tIFJlcDwvZnVsbC10aXRsZT48YWJici0xPk1NV1IuIFJlY29tbWVuZGF0aW9ucyBhbmQgcmVw

b3J0cyA6IE1vcmJpZGl0eSBhbmQgbW9ydGFsaXR5IHdlZWtseSByZXBvcnQuIFJlY29tbWVuZGF0

aW9ucyBhbmQgcmVwb3J0cyAvIENlbnRlcnMgZm9yIERpc2Vhc2UgQ29udHJvbDwvYWJici0xPjwv

YWx0LXBlcmlvZGljYWw+PHBhZ2VzPjEtMzI8L3BhZ2VzPjx2b2x1bWU+NjE8L3ZvbHVtZT48bnVt

YmVyPlJSLTQ8L251bWJlcj48a2V5d29yZHM+PGtleXdvcmQ+QWdlZDwva2V5d29yZD48a2V5d29y

ZD5Db3Vuc2VsaW5nPC9rZXl3b3JkPjxrZXl3b3JkPkZlbWFsZTwva2V5d29yZD48a2V5d29yZD5I

ZXBhY2l2aXJ1cy8qaXNvbGF0aW9uICZhbXA7IHB1cmlmaWNhdGlvbjwva2V5d29yZD48a2V5d29y

ZD5IZXBhdGl0aXMgQywgQ2hyb25pYy9jb21wbGljYXRpb25zLypkaWFnbm9zaXMvbW9ydGFsaXR5

L3ByZXZlbnRpb24gJmFtcDsgY29udHJvbDwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdv

cmQ+PGtleXdvcmQ+TWFsZTwva2V5d29yZD48a2V5d29yZD5NYXNzIFNjcmVlbmluZy8qc3RhbmRh

cmRzPC9rZXl3b3JkPjxrZXl3b3JkPk1pZGRsZSBBZ2VkPC9rZXl3b3JkPjxrZXl3b3JkPk91dGNv

bWUgQXNzZXNzbWVudCAoSGVhbHRoIENhcmUpPC9rZXl3b3JkPjxrZXl3b3JkPlByZXZhbGVuY2U8

L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBGYWN0b3JzPC9rZXl3b3JkPjxrZXl3b3JkPlVuaXRlZCBT

dGF0ZXMvZXBpZGVtaW9sb2d5PC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTI8

L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWcgMTc8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48

aXNibj4xNTQ1LTg2MDEgKEVsZWN0cm9uaWMpJiN4RDsxMDU3LTU5ODcgKExpbmtpbmcpPC9pc2Ju

PjxhY2Nlc3Npb24tbnVtPjIyODk1NDI5PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVy

bHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5paC5nb3YvcHVibWVkLzIyODk1NDI5PC91cmw+

PC9yZWxhdGVkLXVybHM+PC91cmxzPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==

ADDIN EN.CITE.DATA [5] Clinicians should confirm patients testing positive for HCV antibodies for HCV infection. After confirming HCV infection, clinicians should continue with a a pre-treatment checklist and in consultation with a specialist when needed, start patients on appropriate treatment regimens and continuously monitor patients’ progress until they reach a cure.A number of individuals in the IHS patient population have been diagnosed with HCV, but have never been linked to treatment. Over a 30-year period, an estimated 85% of patients with acute HCV infection will go on to develop chronic HCV infection, 34% of patients will go on to develop cirrhosis, and 9% of patients will go on to develop hepatocellular carcinoma. Currently, effective treatments for HCV can reduce HCV viral loads to virtually non-detectable levels without the need for pegylated interferon, a medication associated with a longer duration of treatment and more severe side effects than other treatments. To prevent progression to cirrhosis, hepatocellular carcinoma, and liver failure, clinicians should stage HCV-infected patients, prioritizing patients with advanced liver fibrosis stages to receive immediate treatment. Clinicians should monitor patients with early liver fibrosis stages and also start these patients on treatment as it becomes available.DefinitionsHepatitis C Virus (HCV): International Classification of Disease (ICD)-9: 070.41, 070.44, 070.51, 070.54, 070.70 through 070.71; ICD-10: B17.10, B17.11, B18.2, B19.20, B19.21 and HCV screening as Correct Procedural Terminology (CPT) 86803, or as per local Logical Observation Identifiers Names and Codes (LOINC) or laboratory taxonomies for hepatitis antibody testing.Sustained Virologic Response (SVR): Hepatitis C virus remains undetectable in blood following completion of treatment. SVR is the goal of HCV treatment. SVR, the surrogate marker for HCV cure after completion of therapy is defined as undetectable HCV RNA using a highly sensitive assay 12 weeks following the end of treatment.High-Risk Patient: A patient not currently diagnosed with HCV, but who has participated in certain behaviors, possesses certain medical conditions, and/or falls into certain categories that increase his or her risk of HCV infection. ADDIN EN.CITE <EndNote><Cite><RecNum>9</RecNum><DisplayText>[6]</DisplayText><record><rec-number>9</rec-number><foreign-keys><key app="EN" db-id="p20z9pv99fpf26effrkppwd19tzvsxa9tdvx" timestamp="1415986160">9</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors></contributors><titles><title>Testing Recommendations for Hepatitis C Virus Infection</title></titles><volume>2014</volume><number>November 14</number><dates><pub-dates><date>June 25, 2014</date></pub-dates></dates><pub-location>Atlanta, GA</pub-location><publisher>Centers for Disease Control and Prevention</publisher><urls><related-urls><url> 14</custom2><access-date>November 14, 2014</access-date></record></Cite></EndNote>[6] The following patients should be routinely screened for HCV infection: Vietnam Veterans serving between 1964 and 1975HIV-positive individualsPatients who have ever injected illicit drugs, including those who injected drugs just once or a few times many years agoPatients with certain medical conditions, such as those with hemophilia with receipt of clotting factor concentrates before 1987, those with a current or history of long-term hemodialysis, and those with persistently abnormal alanine aminotransferase levelsPatients who received a transfusion or organ transplant before July 1992 or received blood from a donor who later tested HCV-positivePatients with recognized exposure, for example, health care workers exposed after needle sticks, sharps or mucosal exposures to HCV-positive blood, and children born to HCV-positive mothers at 18 months of age or olderResources National guidelines support the following recommendations. Each recommendation is referenced to an online resource.HCV SCREENINGScreen for HCV-infected patientsClinicians should screen the following categories of patients for HCV antibodies: Patients born from 1945 to 1965 (one-time screening), which national data has shown constitutes 75% of reported cases [5]. Additional age ranges may be included in this screening where local data suggests an elevated HCV burden may exist. Patients determined as high-risk (routine screening unless otherwise noted):Vietnam Veterans serving between 1964 and 1975HIV-positive individuals (at least annual screening for HIV-positive men who have sex with men)Patients who have ever injected illicit drugs, including those who injected drugs just once or a few times many years ago (at least annual screening for current injection drug users)Patients with certain medical conditions, such as those with hemophilia with receipt of clotting factor concentrates before 1987, those with a current or history of long-term hemodialysis, and those with persistently abnormal alanine aminotransferase levelsPatients who received a transfusion or organ transplant before July 1992 or received blood from a donor who later tested HCV-positivePatients with recognized exposure, for example, health care workers exposed after needle sticks, sharps or mucosal exposures to HCV-positive blood, and children born to HCV-positive mothersTest for HCV antibodiesClinicians should screen for HCV in patients identified as belonging to the above categories using immunoassays, such as the OraQuick HCV Rapid Antibody Test (OraSure Technologies) or an FDA-approved, laboratory-conducted HCV antibody assay [7]. The best assay for this purpose is a HCV antibody test with reflex ribonucleic (RNA) confirmation.Test for HCV RNA and determine viral loadClinicians should perform Nucleic Acid Testing (NAT) for patients with reactive immunoassays (and for patients with non-reactive immunoassays if patients are immunocompromised or have been recently exposed to HCV).Clinicians should consider a reactive immunoassay and a negative NAT result to signify a false positive serology or the patient having cleared infection. Clinicians should link patients with a positive NAT result to care; Clinicians should not repeat NAT for patients with a negative NAT result unless patients have been exposed to HCV within the past 6 months, patients present with clinical evidence of disease, or specimens have been mishandled or improperly stored.Clinicians should determine a quantitative HCV RNA viral load to provide baseline markers to determine treatment progress.Patients who are positive for HCV+ Ab but HCV RNA negative may have spontaneously cleared the virus. This occurs in an estimated 15%-25% of HCV exposed individuals. Such patients need no further follow up for HCV (except counseling on risk behaviors as appropriate) and will test positive for HCV Ab+ during their lifetimes. Consequently, any subsequent testing for HCV in this population subset should immediately include RNA testing.Perform laboratory evaluationUpon confirming chronic HCV infection, clinicians should perform the following set of additional laboratory tests (where tests are available):General laboratory evaluation, including complete blood count, platelet count, thyroid function tests, and renal function testsTests to determine hepatic inflammation, such as alanine aminotransferase or aspartate aminotransferaseTests to determine hepatobiliary disease, such as bilirubin and alkaline phosphataseTests to determine hepatic function, such as serum albumin and prothrombin timeAssays to detect significant co-infections, such as hepatitis A antibody, hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody, HIV antibodyPerform complete patient history and examinationUpon confirming chronic HCV infection, clinicians should perform complete patient medical histories and physical examinations. Clinicians should determine patients’ risk factors for acquiring HCV infection, psychiatric history, significant comorbidities, co-infection with other viruses, stigmata of chronic liver disease, clinical manifestations attributable to HCV infection, history of prior treatment, and previous assessment of liver fibrosis. ADDIN EN.CITE <EndNote><Cite><Author>Ramers</Author><Year>2013</Year><RecNum>11</RecNum><DisplayText>[8]</DisplayText><record><rec-number>11</rec-number><foreign-keys><key app="EN" db-id="p20z9pv99fpf26effrkppwd19tzvsxa9tdvx" timestamp="1416412056">11</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Ramers, Christian D.</author></authors></contributors><titles><title>Initial Evaluation of Persons with Chronic Hepatitis C</title></titles><volume>2014</volume><number>November 19</number><dates><year>2013</year><pub-dates><date>December 9, 2013</date></pub-dates></dates><publisher>Family Health Centers of San Diego</publisher><urls><related-urls><url> 19</custom2></record></Cite></EndNote>[8] Upon performing complete patient medical histories and physical examinations, clinicians should treat conditions that may delay HCV treatment and/or prevent patients from obtaining sustained virologic response.Clinicians should also assess patients’ alcohol histories to determine dependence that may delay treatment and/or prevent patients from achieving a sustained virologic response.Psychiatric historyWhereas HCV treatments including interferon (a medication associated with neuropsychiatric side effects) are no longer necessary to develop a sustained virologic response, clinicians should still assess patients’ past or current psychiatric issues during the initial visit. Psychiatric issues are generally not contraindications for HCV treatment. Upon diagnosing psychiatric issues, clinicians should link patients to psychiatric treatment, as appropriate.Significant comorbiditiesClinicians should determine secondary causes of liver disease, such as non-alcoholic fatty liver disease, alcoholic hepatitis, or autoimmune hepatitis. Clinicians should also advise obese patients to lose weight prior to beginning HCV treatment, and cessation of alcohol and tobacco use.Co-infection with other virusesClinicians should screen HCV-infected patients for hepatitis A virus, hepatitis B virus, and human immunodeficiency virus (HIV). If patient is not immune to hepatitis A or B, consider vaccination.Stigmata of chronic liver diseaseClinicians may consider the presence of the following physical signs and symptoms (in decreasing order of the likelihood ratio of cirrhosis) as indicators of cirrhosis: caput medusae/dilated abdominal wall vessels, loss of body/pubic hair, hepatic encephalopathy, gynecomastia, ascites, spider angiomata, palmar erythema, jaundice and scleral icterus, and liver stiffness.Clinical manifestationsClinicians should determine extrahepatic clinical manifestations of chronic HCV infection, such as arthralgias, neuropathy, nephropathy, glomerulonephritis, livedo reticularis, lichen planus, and cold agglutinin disease.History of prior treatmentClinicians should determine if patients have previously undergone HCV treatment. If patients have failed to obtain sustained virologic response with previous HCV treatment, clinicians should determine the following with regard to previous HCV treatment: medications, duration, timing, patient’s degree of adherence, adverse effects, and when possible, viral kinetics and outcome.Previous assessment of liver fibrosisClinicians should determine whether patients have previously had a liver biopsy. For patients who have had a liver biopsy, clinicians should record the date of the biopsy, the sample size, the fibrosis scoring system, and the fibrosis score. Clinicians should also note any previously performed non-invasive tests for determining liver fibrosis scores.Stage HCV Liver FibrosisAlthough the gold standard to stage hepatic fibrosis is by performing a liver biopsy with histologic analysis, noninvasive testing with ultrasound transient elastography (FibroScanTM) or blood test staging methods are widely used, acceptable, and more feasible. These methods include two of the following non-invasive tests for indirect markers of cirrhosis: Aspartate Aminotransferase-to-Platelet Ratio Index (APRI), Fibrosis-4 (FIB-4), and FibroSure. When using non-invasive tests, if both tests determine the fibrosis score as F1, treatment is optional if patients have no contraindications; if both tests determine the fibrosis score as F2 or above, clinicians should begin patients on antiviral therapy if patient has no contraindications. If tests determine disparate results, clinicians should consider following up with a liver biopsy or FibroScan. ADDIN EN.CITE <EndNote><Cite><Author>Bhogal</Author><Year>2012</Year><RecNum>15</RecNum><DisplayText>[9]</DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="p20z9pv99fpf26effrkppwd19tzvsxa9tdvx" timestamp="1417037078">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bhogal, H.</author><author>Sterling, R. K.</author></authors></contributors><auth-address>Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA.</auth-address><titles><title>Staging of liver disease: which option is right for my patient?</title><secondary-title>Infect Dis Clin North Am</secondary-title><alt-title>Infectious disease clinics of North America</alt-title></titles><periodical><full-title>Infect Dis Clin North Am</full-title><abbr-1>Infectious disease clinics of North America</abbr-1></periodical><alt-periodical><full-title>Infect Dis Clin North Am</full-title><abbr-1>Infectious disease clinics of North America</abbr-1></alt-periodical><pages>849-61</pages><volume>26</volume><number>4</number><keywords><keyword>Algorithms</keyword><keyword>Biological Markers/analysis</keyword><keyword>Biopsy</keyword><keyword>Diagnostic Imaging</keyword><keyword>Hepatitis C, Chronic/diagnosis/metabolism/*pathology/virology</keyword><keyword>Humans</keyword><keyword>Liver Cirrhosis/diagnosis/metabolism/*pathology/*virology</keyword><keyword>Severity of Illness Index</keyword></keywords><dates><year>2012</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1557-9824 (Electronic)&#xD;0891-5520 (Linking)</isbn><accession-num>23083819</accession-num><urls><related-urls><url>;[9]Preventive care and counseling for chronic HCV patientsBefore patients begin treatment, have a confirmed positive HCV RNA level, preferably quantitative in nature. A genotype test will also be needed to determine the recommended course of treatment.? Clinicians should prioritize patients with advanced or compensated cirrhosis (F3 and F4 fibrosis scores, respectively), patients with severe or extrahepatic HCV, and liver transplant recipients to receive immediate treatment. [10-13]Patients should also be vaccinated for Hepatitis A and B, if immunity is not detected.While treatment may depend on a variety of factors, linkage to care for patients with chronic HCV infection should be as timely as possible.? IHS sites should determine what is the best course of action for linkage to care that are the most feasible for their patients, based on the overall case load and acuity.? Linkage to care can entail multiple options such as external referrals to specialists, or treatment within the facility with on-site (visiting specialist clinic) or remote specialist support (e.g. telehealth) for primary care clinician-led HCV treatment programs.All HCV-confirmed patients should be counseled in regards to reducing the risk for spread of HCV infection, the risks for sexual partners, and the avoidance of hepatotoxic substances (OTC and prescription drugs, alcohol, and supplement use).When appropriate, clinicians should counsel patients on weight loss and diet. Clinicians should advise patients about all restrictions and/or considerations before patients begin treatment. A pre-treatment checklist is in the appendix of this policy. Approach to Monitoring After Receiving HCV Therapy: The approach to monitoring patients following completion of a course of HCV therapy depends entirely on the patient's response to therapy. Three main scenarios exist: (a) the patient achieved an SVR, (b) the patient completed therapy but did not achieve an SVR, or (c) the patient had an inadequate treatment course because of adherence problems, intolerance, or laboratory toxicity necessitating premature discontinuation of the treatment regimen.Monitoring Patients who Achieved an SVR: Patients who have an undetectable HCV RNA at week 12 (or later) after completing HCV therapy are considered to have achieved an SVR. In a review by Welker of 44 studies involving more than 4,228 patients who achieved an SVR with an interferon-based regimen, 97% of patients maintained the SVR during the long-term follow-up period. Some experts will obtain an HCV RNA level 24 weeks after completing treatment in selected patients. In a more recent review by Manns, more than 99.2% of 1002 patients who achieved an SVR12 with interferon- or peginterferon-based therapy maintained undetectable HCV RNA levels for 5 years. Comparable data on the long-term durability of treatment response with all-oral DAA therapy is not yet available, but it is generally thought that SVR12 responses will represent sustained HCV clearance similar to that seen with interferon-based therapy. All patients who achieve an SVR should clearly understand they are not immune to HCV and can become reinfected with HCV. The AASLD/IDSA Guidance stratifies the follow-up for persons who achieve an SVR based on the degree of hepatic fibrosis and the risk of developing reinfection.Patients with without advanced fibrosis (Metavir stage F0-F2): These patients do not need special monitoring or follow-up specifically for HCV or liver care. This recommendation is based on data that show patients with SVR following HCV treatment generally do not have further progression of HCV-related liver fibrosis.Patients with Advanced Fibrosis (Metavir stage F3-F4): Although fibrosis may improve in these patients, they are considered to have persistent risk, albeit lower than before achieving an SVR, for developing hepatocellular carcinoma. Accordingly, these patients should have surveillance for hepatocellular carcinoma (HCC) with hepatic ultrasound every 6 months. In addition, patients with cirrhosis (F4 fibrosis) should have a baseline upper endoscopy to screen for varices, unless this has previously been done. Patients identified with varices should receive appropriate management and follow-up.Patients with Ongoing Risk of HCV Reinfection: Regardless of the degree of hepatic fibrosis, all patients with ongoing risk for acquiring HCV should have periodic assessment for HCV reinfection and counseling on prevention of reinfection. Obtaining HCV antibody does not provide useful information in these individuals with known prior HCV infection since they are highly likely to remain antibody positive. Thus, reassessment should consist of a quantitative HCV RNA level. In addition, for these patients, any flare in liver enzyme tests should prompt evaluation for reinfection with a quantitative HCV RNA level.Patients with Persistently Abnormal Liver Tests: Any patient that develops persistently elevated liver tests should undergo evaluation for possible other causes of liver disease, such as alcohol use, iron overload, or fatty liver disease.Monitoring for Patients who do not Achieve SVR: The AASLD/IDSA guidance recommends the following for patients who did not achieve an SVR with HCV therapy. All Patients: For all patients who did not achieve an SVR, follow-up laboratory testing should occur every 6 to 12 months with a hepatic function panel, complete blood count, and international normalized ratio. In addition, these patients should have periodic reevaluation for retreatment, especially as new options become available. It is important these patients receive counseling for alcohol abstinence (or safe use) and avoidance of hepatotoxic medications.Patients with Advanced Fibrosis (Metavir Stage F3-F4): These patients should have surveillance for hepatocellular carcinoma with hepatic ultrasound every 6 months. In addition, patients with cirrhosis (F4 fibrosis) should have a baseline upper endoscopy to screen for varices, unless this has previously been done. Patients identified with varices should receive appropriate management and follow-up.Reporting Health providers in FORMTEXT ????? are required to report cases of chlamydia, gonorrhea, syphilis, genital herpes and chancroid to the local health department. STI reporting forms are available at: FORMTEXT ?????.Questions and ResourcesThis sample policy can be adapted for local use. These documents and accompanying information sheets can be found on the IHS HCV Program website: . Questions regarding HCV diagnosis, treatment, patient and partner follow-up, and reporting should be directed to the appropriate local tribal health department or to the respective state HCV program.HCV educational resources for providers and tribal health departments are available from the CDC [] and the Northwest Portland Area Indian Health Board [ Brochure and Radio PSAs]. Contact Information for Local Health Department FORMTEXT <<insert address for reporting>> FORMTEXT <<insert phone number>> FORMTEXT <<insert fax number>>Appendix(i) Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965. MMWR 2012; Vol. 61 (RR-4)(ii) Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-Related Chronic Disease. MMWR 1998; Vol. 47 (RR-19)(iii) Recommended Testing Sequence for Identifying Current Hepatitis C Virus (HCV) Infection *For persons who might have been exposed to HCV within the past 6 months, testing for HCV RNA or follow-up testing for HCV antibody is recommended. For persons who are immunocompromised, testing for HCV RNA can be considered. ? To differentiate past, resolved HCV infection from biologic false positivity for HCV antibody, testing with another HCV antibody assay can be considered. Repeat HCV RNA testing if the person tested is suspected to have had HCV exposure within the past 6 months or has clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test specimen.Source: CDC. Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR 2013;62(18).00*For persons who might have been exposed to HCV within the past 6 months, testing for HCV RNA or follow-up testing for HCV antibody is recommended. For persons who are immunocompromised, testing for HCV RNA can be considered. ? To differentiate past, resolved HCV infection from biologic false positivity for HCV antibody, testing with another HCV antibody assay can be considered. Repeat HCV RNA testing if the person tested is suspected to have had HCV exposure within the past 6 months or has clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test specimen.Source: CDC. Testing for HCV infection: An update of guidance for clinicians and laboratorians. MMWR 2013;62(18).(iv) Screening for Hepatitis C Virus Infection in Adults, American Association for the Study of Liver Disease (v) Natural History of Hepatitis C Viral Infection PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYWFzb3VteTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+

PFJlY051bT4xNDwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMTFdPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjE0PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0icDIwejlwdjk5ZnBmMjZlZmZya3Bwd2QxOXR6dnN4YTl0ZHZ4IiB0aW1lc3RhbXA9IjE0

MTcwMzUwMTEiPjE0PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg

QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYWFz

b3VteSwgQi48L2F1dGhvcj48YXV0aG9yPldlZGVtZXllciwgSC48L2F1dGhvcj48L2F1dGhvcnM+

PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5IYW5ub3ZlciBNZWRpY2FsIFNjaG9vbCwgQ2Fy

bC1OZXViZXJnLVN0ci4xLCAzMDYyNSBIYW5ub3ZlciwgR2VybWFueS48L2F1dGgtYWRkcmVzcz48

dGl0bGVzPjx0aXRsZT5OYXR1cmFsIGhpc3Rvcnkgb2YgYWN1dGUgYW5kIGNocm9uaWMgaGVwYXRp

dGlzIEM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QmVzdCBQcmFjdCBSZXMgQ2xpbiBHYXN0cm9l

bnRlcm9sPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5CZXN0IHByYWN0aWNlICZhbXA7IHJl

c2VhcmNoLiBDbGluaWNhbCBnYXN0cm9lbnRlcm9sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBl

cmlvZGljYWw+PGZ1bGwtdGl0bGU+QmVzdCBQcmFjdCBSZXMgQ2xpbiBHYXN0cm9lbnRlcm9sPC9m

dWxsLXRpdGxlPjxhYmJyLTE+QmVzdCBwcmFjdGljZSAmYW1wOyByZXNlYXJjaC4gQ2xpbmljYWwg

Z2FzdHJvZW50ZXJvbG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1

bGwtdGl0bGU+QmVzdCBQcmFjdCBSZXMgQ2xpbiBHYXN0cm9lbnRlcm9sPC9mdWxsLXRpdGxlPjxh

YmJyLTE+QmVzdCBwcmFjdGljZSAmYW1wOyByZXNlYXJjaC4gQ2xpbmljYWwgZ2FzdHJvZW50ZXJv

bG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjQwMS0xMjwvcGFnZXM+PHZvbHVt

ZT4yNjwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BY3V0ZSBE

aXNlYXNlPC9rZXl3b3JkPjxrZXl3b3JkPkFudGl2aXJhbCBBZ2VudHMvdGhlcmFwZXV0aWMgdXNl

PC9rZXl3b3JkPjxrZXl3b3JkPkNhcmNpbm9tYSwgSGVwYXRvY2VsbHVsYXIvZXRpb2xvZ3kvcHJl

dmVudGlvbiAmYW1wOyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPkRpc2Vhc2UgUHJvZ3Jlc3Np

b248L2tleXdvcmQ+PGtleXdvcmQ+SGVwYWNpdmlydXM8L2tleXdvcmQ+PGtleXdvcmQ+KkhlcGF0

aXRpcyBDL2NvbXBsaWNhdGlvbnMvZGlhZ25vc2lzL2RydWcgdGhlcmFweS9tb3J0YWxpdHkvdHJh

bnNtaXNzaW9uPC9rZXl3b3JkPjxrZXl3b3JkPipIZXBhdGl0aXMgQywgQ2hyb25pYy9jb21wbGlj

YXRpb25zL2RpYWdub3Npcy9kcnVnIHRoZXJhcHkvbW9ydGFsaXR5L3RyYW5zbWlzc2lvbjwva2V5

d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TGl2ZXIgQ2lycmhvc2lzL2V0

aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkxpdmVyIE5lb3BsYXNtcy9ldGlvbG9neS9wcmV2ZW50

aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBGYWN0b3JzPC9rZXl3b3Jk

Pjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWc8

L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTMyLTE5MTYgKEVsZWN0cm9uaWMpJiN4

RDsxNTIxLTY5MTggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIzMTk5NTAwPC9hY2Nl

c3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5p

aC5nb3YvcHVibWVkLzIzMTk5NTAwPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJv

bmljLXJlc291cmNlLW51bT4xMC4xMDE2L2ouYnBnLjIwMTIuMDkuMDA5PC9lbGVjdHJvbmljLXJl

c291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NYWFzb3VteTwvQXV0aG9yPjxZZWFyPjIwMTI8L1llYXI+

PFJlY051bT4xNDwvUmVjTnVtPjxEaXNwbGF5VGV4dD5bMTFdPC9EaXNwbGF5VGV4dD48cmVjb3Jk

PjxyZWMtbnVtYmVyPjE0PC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBk

Yi1pZD0icDIwejlwdjk5ZnBmMjZlZmZya3Bwd2QxOXR6dnN4YTl0ZHZ4IiB0aW1lc3RhbXA9IjE0

MTcwMzUwMTEiPjE0PC9rZXk+PC9mb3JlaWduLWtleXM+PHJlZi10eXBlIG5hbWU9IkpvdXJuYWwg

QXJ0aWNsZSI+MTc8L3JlZi10eXBlPjxjb250cmlidXRvcnM+PGF1dGhvcnM+PGF1dGhvcj5NYWFz

b3VteSwgQi48L2F1dGhvcj48YXV0aG9yPldlZGVtZXllciwgSC48L2F1dGhvcj48L2F1dGhvcnM+

PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5IYW5ub3ZlciBNZWRpY2FsIFNjaG9vbCwgQ2Fy

bC1OZXViZXJnLVN0ci4xLCAzMDYyNSBIYW5ub3ZlciwgR2VybWFueS48L2F1dGgtYWRkcmVzcz48

dGl0bGVzPjx0aXRsZT5OYXR1cmFsIGhpc3Rvcnkgb2YgYWN1dGUgYW5kIGNocm9uaWMgaGVwYXRp

dGlzIEM8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+QmVzdCBQcmFjdCBSZXMgQ2xpbiBHYXN0cm9l

bnRlcm9sPC9zZWNvbmRhcnktdGl0bGU+PGFsdC10aXRsZT5CZXN0IHByYWN0aWNlICZhbXA7IHJl

c2VhcmNoLiBDbGluaWNhbCBnYXN0cm9lbnRlcm9sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBl

cmlvZGljYWw+PGZ1bGwtdGl0bGU+QmVzdCBQcmFjdCBSZXMgQ2xpbiBHYXN0cm9lbnRlcm9sPC9m

dWxsLXRpdGxlPjxhYmJyLTE+QmVzdCBwcmFjdGljZSAmYW1wOyByZXNlYXJjaC4gQ2xpbmljYWwg

Z2FzdHJvZW50ZXJvbG9neTwvYWJici0xPjwvcGVyaW9kaWNhbD48YWx0LXBlcmlvZGljYWw+PGZ1

bGwtdGl0bGU+QmVzdCBQcmFjdCBSZXMgQ2xpbiBHYXN0cm9lbnRlcm9sPC9mdWxsLXRpdGxlPjxh

YmJyLTE+QmVzdCBwcmFjdGljZSAmYW1wOyByZXNlYXJjaC4gQ2xpbmljYWwgZ2FzdHJvZW50ZXJv

bG9neTwvYWJici0xPjwvYWx0LXBlcmlvZGljYWw+PHBhZ2VzPjQwMS0xMjwvcGFnZXM+PHZvbHVt

ZT4yNjwvdm9sdW1lPjxudW1iZXI+NDwvbnVtYmVyPjxrZXl3b3Jkcz48a2V5d29yZD5BY3V0ZSBE

aXNlYXNlPC9rZXl3b3JkPjxrZXl3b3JkPkFudGl2aXJhbCBBZ2VudHMvdGhlcmFwZXV0aWMgdXNl

PC9rZXl3b3JkPjxrZXl3b3JkPkNhcmNpbm9tYSwgSGVwYXRvY2VsbHVsYXIvZXRpb2xvZ3kvcHJl

dmVudGlvbiAmYW1wOyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPkRpc2Vhc2UgUHJvZ3Jlc3Np

b248L2tleXdvcmQ+PGtleXdvcmQ+SGVwYWNpdmlydXM8L2tleXdvcmQ+PGtleXdvcmQ+KkhlcGF0

aXRpcyBDL2NvbXBsaWNhdGlvbnMvZGlhZ25vc2lzL2RydWcgdGhlcmFweS9tb3J0YWxpdHkvdHJh

bnNtaXNzaW9uPC9rZXl3b3JkPjxrZXl3b3JkPipIZXBhdGl0aXMgQywgQ2hyb25pYy9jb21wbGlj

YXRpb25zL2RpYWdub3Npcy9kcnVnIHRoZXJhcHkvbW9ydGFsaXR5L3RyYW5zbWlzc2lvbjwva2V5

d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+TGl2ZXIgQ2lycmhvc2lzL2V0

aW9sb2d5PC9rZXl3b3JkPjxrZXl3b3JkPkxpdmVyIE5lb3BsYXNtcy9ldGlvbG9neS9wcmV2ZW50

aW9uICZhbXA7IGNvbnRyb2w8L2tleXdvcmQ+PGtleXdvcmQ+UmlzayBGYWN0b3JzPC9rZXl3b3Jk

Pjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTI8L3llYXI+PHB1Yi1kYXRlcz48ZGF0ZT5BdWc8

L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTMyLTE5MTYgKEVsZWN0cm9uaWMpJiN4

RDsxNTIxLTY5MTggKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24tbnVtPjIzMTk5NTAwPC9hY2Nl

c3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRwOi8vd3d3Lm5jYmkubmxtLm5p

aC5nb3YvcHVibWVkLzIzMTk5NTAwPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxzPjxlbGVjdHJv

bmljLXJlc291cmNlLW51bT4xMC4xMDE2L2ouYnBnLjIwMTIuMDkuMDA5PC9lbGVjdHJvbmljLXJl

c291cmNlLW51bT48L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=

ADDIN EN.CITE.DATA [13](vi) Evaluation of Fibrosis in Patients with Chronic HCV ADDIN EN.CITE <EndNote><Cite><Author>Bhogal</Author><Year>2012</Year><RecNum>15</RecNum><DisplayText>[9]</DisplayText><record><rec-number>15</rec-number><foreign-keys><key app="EN" db-id="p20z9pv99fpf26effrkppwd19tzvsxa9tdvx" timestamp="1417037078">15</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Bhogal, H.</author><author>Sterling, R. K.</author></authors></contributors><auth-address>Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA.</auth-address><titles><title>Staging of liver disease: which option is right for my patient?</title><secondary-title>Infect Dis Clin North Am</secondary-title><alt-title>Infectious disease clinics of North America</alt-title></titles><periodical><full-title>Infect Dis Clin North Am</full-title><abbr-1>Infectious disease clinics of North America</abbr-1></periodical><alt-periodical><full-title>Infect Dis Clin North Am</full-title><abbr-1>Infectious disease clinics of North America</abbr-1></alt-periodical><pages>849-61</pages><volume>26</volume><number>4</number><keywords><keyword>Algorithms</keyword><keyword>Biological Markers/analysis</keyword><keyword>Biopsy</keyword><keyword>Diagnostic Imaging</keyword><keyword>Hepatitis C, Chronic/diagnosis/metabolism/*pathology/virology</keyword><keyword>Humans</keyword><keyword>Liver Cirrhosis/diagnosis/metabolism/*pathology/*virology</keyword><keyword>Severity of Illness Index</keyword></keywords><dates><year>2012</year><pub-dates><date>Dec</date></pub-dates></dates><isbn>1557-9824 (Electronic)&#xD;0891-5520 (Linking)</isbn><accession-num>23083819</accession-num><urls><related-urls><url>;[9](vii) When and in Whom to Initiate HCV Therapy: Factors Associated with Accelerated Fibrosis Progression ADDIN EN.CITE <EndNote><Cite><Year>2014</Year><RecNum>16</RecNum><DisplayText>[10]</DisplayText><record><rec-number>16</rec-number><foreign-keys><key app="EN" db-id="p20z9pv99fpf26effrkppwd19tzvsxa9tdvx" timestamp="1417625702">16</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors></contributors><titles><title>When and in Whom to Initiate HCV Therapy</title><secondary-title>Recommendations for Testing, Managing, and Treating Hepatitis C</secondary-title></titles><volume>2014</volume><number>December 3</number><dates><year>2014</year><pub-dates><date>November 20, 2014</date></pub-dates></dates><publisher>American Association for the Study of Liver Diseases; Infectious Diseases Society of America</publisher><urls><related-urls><url> 3</custom2></record></Cite></EndNote>[10]HostViralNon-ModifiableGenotype 3Fibrosis stageCo-infection with hepatitis B virus (HBV)Inflammation gradeCo-infection with human immunodeficiency virus (HIV)Older age at time of infectionMale sexOrgan transplantModifiableAlcohol consumptionObesityNonalcoholic fatty liver diseaseInsulin resistance(viii) Hepatitis C Pre-Treatment Checklist: ? Labs: Immediately prior: □ Pregnancy test □ Uric Acid (with ribavirin) Within 1 month: □ Complete Blood Count with differential □ Comprehensive Metabolic Panel (If GFR <30, do not start treatment; consult Liver Disease Specialist) □ PT/INR □ HCV RNA Within 3 months: □ Genotype confirmation Within 6 months: □ AFP □ TSH □ A1C or Fasting Glucose □ Vitamin D 25OH Within 1 year: □ HIV screening? Screen & Review: AUDIT-C __PHQ-9 ___Drug & Alcohol Screen (at discretion of provider) ? Vaccine Status/Screening: Hepatitis A & B vaccinations are recommended for all persons with HCV □ Hepatitis A (If vaccine status is unknown, check hep A total IgG) □ Hepatitis B (If vaccine status is unknown, check HBsAg & HBsAb) Other vaccines as appropriate: □ Flu (annually) □ Pneumococcal-13 (≥ age 65 or high risk/immunosuppressed) □ Pneumococcal-23 (≥ age 50 AN/AI living in Alaska or high risk) □ Td (once every 10 years) OR Tdap (once) □ Zoster (≥ age 60) Pre-Treatment Clinical Evaluation: □ Medical history including liver disease history and past hepatitis C treatment □ Hypertension/Diabetes controlled □ Counsel about smoking cessation □ Counsel about pregnancy prevention (see Treatment Agreement) □ Review all medications; check for drug interactions with treatment meds □ Physical Exam □ Hepatitis C Treatment Agreement reviewed and signed □ ECG (If treatment includes ribavirin or peginterferon, over age 65 or h/o cardiac disease) If treatment includes peginterferon complete the following: □ Mental Health Evaluation if h/o depression or other psychiatric condition □ Stress Test (h/o cardiac disease, prior to peginterferon or ribavirin) □ Dilated retinal/ophthalmology exam (peginterferon candidates only who have HTN, HLD,DM, or h/o retinal disease or blindness)References ADDIN EN.REFLIST 1.Denniston, M.M., et al., Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med, 2014. 160(5): p. 293-300.2.Prevention, C.f.D.C.a. Surveillance for Viral Hepatitis – United States, 2012. 2014 9/2/14 [cited 2014 10/27]; Available from: , A., et al., Mortality caused by chronic liver disease among American Indians and Alaska Natives in the United States, 1999-2009. Am J Public Health, 2014. 104 Suppl 3: p. S350-8.4.Younossi, Z.M., et al., Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat, 2013. 20(8): p. 550-5.5.Smith, B.D., et al., Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep, 2012. 61(RR-4): p. 1-32.6.Testing Recommendations for Hepatitis C Virus Infection. June 25, 2014 [cited 2014 November 14]; Available from: . American Association for the Study of Liver Diseases, (accessed Aug 25, 2016).8.Panneer, N., et al., HIV and hepatitis C virus infection in the United States: whom and how to test. Clin Infect Dis, 2014. 59(6): p. 875-82.9.Ramers, C.D. Initial Evaluation of Persons with Chronic Hepatitis C. 2013 December 9, 2013 [cited 2014 November 19]; Available from: , H. and R.K. Sterling, Staging of liver disease: which option is right for my patient? Infect Dis Clin North Am, 2012. 26(4): p. 849-61.11. University of Washington, (accessed Aug 25, 2016).12.Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-36.13. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158:807-20.14.When and in Whom to Initiate HCV Therapy. Recommendations for Testing, Managing, and Treating Hepatitis C 2014 November 20, 2014 [cited 2014 December 3]; Available from: . ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download